Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers

Background: Cannabidiol (CBD) is a cannabinoid of potential interest for the treatment of substance use disorders. Our aim was to review the outcome measures, surrogate endpoints, and biomarkers in published and ongoing randomized clinical trials. Methods: We conducted a search in PubMed, Web of Sci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Psychiatry
Main Authors: Morel, Alix, Lebard, Pierre, Dereux, Alexandra, Azuar, Julien, Questel, Frank, Bellivier, Frank, Marie-Claire, Cynthia, Fatséas, Mélina, Vorspan, Florence, Bloch, Vanessa
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Psychiatry
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7937926/
https://ncbi.nlm.nih.gov/pubmed/33692705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpsyt.2021.565617
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados